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ABSTRACT
Objectives: To compare the effectiveness of
pharmacist medication review, with or without
pharmacist prescribing, with standard care, for patients
with chronic pain.
Design: An exploratory randomised controlled trial.
Setting: Six general practices with prescribing
pharmacists in Grampian (3) and East Anglia (3).
Participants: Patients on repeat prescribed pain
medication (4815) were screened by general
practitioners (GPs), and mailed invitations (1397). 196
were randomised and 180 (92%) completed. Exclusion
criteria included: severe mental illness, terminally ill,
cancer related pain, history of addiction.
Randomisation and intervention: Patients were
randomised using a remote telephone service to:
(1) pharmacist medication review with face-to-face
pharmacist prescribing; (2) pharmacist medication
review with feedback to GP and no planned patient
contact or (3) treatment as usual (TAU). Blinding was
not possible.
Outcome measures: Outcomes were the SF-12v2,
the Chronic Pain Grade (CPG), the Health Utilities Index
3 and the Hospital Anxiety and Depression Scale
(HADS). Outcomes were collected at 0, 3 and
6 months.
Results: In the prescribing arm (n=70) two patients
were excluded/nine withdrew. In the review arm (n=63)
one was excluded/three withdrew. In the TAU arm
(n=63) four withdrew. Compared with baseline,
patients had an improved CPG in the prescribing arm,
47.7% (21/44; p=0.003) and in the review arm, 38.6%
(17/44; p=0.001), but not the TAU group, 31.3% (15/
48; ns). The SF-12 Physical Component Score showed
no effect in the prescribing or review arms but
improvement in TAU (p=0.02). The SF-12 Mental
Component Score showed no effect for the prescribing
or review arms and deterioration in the TAU arm
(p=0.002). HADS scores improved within the
prescribing arm for depression (p=0.022) and anxiety
(p=0.007), between groups (p=0.022 and p=0.045,
respectively).
Conclusions: This is the first randomised controlled
trial of pharmacist prescribing in the UK, and suggests
that there may be a benefit for patients with chronic
pain. A larger trial is required.
Trial registration: www.isrctn.org/ISRCTN06131530.
Medical Research Council funding.
INTRODUCTION
Chronic pain (pain lasting more than
3 months) affects up to half the adult UK
population, and is considered severely limit-
ing in about 15% of cases.1 Recovery is
uncommon with nearly 80% of those identi-
ﬁed with chronic pain at baseline still report-
ing chronic pain 4 years later.2 It adversely
affects many aspects of a person’s physical
and psychological health, and social and eco-
nomic well-being.3–6
In the UK, most patients with chronic pain
present, and are managed, in primary care.7
ARTICLE SUMMARY
Article focus
▪ Chronic pain (lasting >3 months) affects up to
half the adult population, most of whom are pri-
marily managed in primary care but prescribing
is often suboptimal.
▪ Pharmacists now have prescribing rights but no
published research has compared the effective-
ness of their prescribing with that of GPs.
▪ The hypothesis was that pharmacist advice (with
or without pharmacist prescribing) would lead to
better outcomes than usual care.
Key messages
▪ The findings suggest that there may be improved
pain-related outcomes for patients receiving
pain-related care from a pharmacist prescriber.
▪ A larger trial is called for.
Strengths and limitations of this study
▪ This the first randomised controlled trial of
pharmacist prescribing in the UK looking at
patient reported clinical outcomes.
▪ The study was designed as an exploratory trial
so no power calculation was done.
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Although non-pharmacological treatments are available,
these are accessed by few patients, with mixed success.8–10
Analgesics prescribed in primary care remain the main-
stay of treatment,4 representing substantial workload and
cost. Suboptimal prescribing may lead to poor pain
control and other adverse patient outcomes. One study
found that the most common medications involved in
adverse drug reaction-related emergency admissions
involved non-steroidal anti-inﬂammatory drugs
(NSAIDs)11 which are commonly used to manage pain.
Improved prescribing could result in better outcomes
and remove the need for more costly, scarce,
alternatives.
Pharmacists working in UK general practices are well-
placed to improve pain pharmacotherapy because of
their expertise in therapeutics, understanding of the
polypharmacy regimens12 frequently used in chronic
pain management and established relationships with
other primary care colleagues. In the UK National
Health Service (NHS), recent regulatory changes now
allow accredited pharmacists (as well as some other
healthcare professionals such as nurses) to prescribe
prescription-only medicines.13 Pharmacists can either be
qualiﬁed as supplementary prescribers, in which case
they operate within an agreed clinical management plan
(CMP) in partnership with the doctor and patient, or as
an independent prescriber, in which case they can
either prescribe completely independently or within a
CMP.
However, despite the increasing number of non-
medical prescribers, including pharmacists, there has
been no rigourous comparisons of the outcomes of non-
medical versus general practitioner (GP) prescribing.
This information is needed to assess the clinical effect-
iveness of different care models.
This paper reports ﬁndings from an exploratory ran-
domised controlled trial (RCT) comparing pharmacist
medication review, with or without pharmacist prescrib-
ing, with standard care for patients with chronic pain.
Development of the trial was informed by earlier feasi-
bility work.14 15
The a priori hypothesis was that, in patients with
chronic pain, pharmacist advice (with or without
pharmacist prescribing) would lead to better patient
functioning and/or better pain control at 6 months,
than treatment as usual (TAU).
METHODS
Regulatory issues
Ethical approval was granted by the National Research
Ethics Service Committee—North of Scotland (refer-
ence number 09/S0801/107). NHS Research and
Development approval was granted by NHS Grampian
and East Norfolk & Waveney Research Governance
Committees. Patients gave informed consent before
taking part.
Design
An open, exploratory RCT in which patients were rando-
mised to one of the three study arms. Participants were
not blind to allocated treatment arm due to the nature
of the intervention.
Recruitment of practices and independent prescribing
pharmacists
Practices in the Grampian Health Board area, Scotland
(n=18) and East Anglia region of England (n=4) known
to have an attached Royal Pharmaceutical Society of
Great Britain registered independent pharmacist pre-
scriber, were eligible to take part. From those indicating
a willingness to participate, convenience sampling was
used to identify six general practices: three in Grampian
and three in East Anglia.
Patient inclusion and exclusion criteria
Patients registered with the recruited practices were eli-
gible for inclusion if they were over 18 years of age,
living in their own houses and receiving regular pre-
scribed medication for pain. Patients were identiﬁed by
a computerised search14 of the drug records of all indivi-
duals registered with the practice, to identify those who
had received either two or more acute prescriptions,
and/or one repeat prescription within the last 120 days,
for an analgesic (British National Formulary (BNF
section 4.7) and/or NSAID (BNF section 10.1.1).
Medications that can be used for analgesia but whose
primary indication is not chronic pain (eg triptans, anti-
epileptics or antidepressants) were excluded as these
drugs identify few additional eligible patients.16 In
accordance with trial criteria, GPs excluded and
recorded reasons for patients who had: a concomitant
severe mental health problem or terminal illness; had
suffered recent bereavement; had a known alcohol or
drug addiction; suffered pain caused by cancer or other
malignancy; were unable to give informed consent;
other (unspeciﬁed) reasons.
Patient recruitment
Eligible patients were sent an invitation pack (letter,
information sheet, consent form) by practice staff
between March and June 2010. Consent forms were
returned directly to the researchers, who sent out a base-
line questionnaire. Patients returning completed ques-
tionnaires were randomised by the researcher using a
telephone randomisation service with a random number
allocation which ensured allocation concealment. The
allocation sequence was 1 : 1 : 1.
Intervention
All participating pharmacists took part in a 2-day course
updating them about pain management. As part of the
training, participants deﬁned and agreed the treatment
algorithm they would all use.
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‘Prescribing’ arm
Pharmacists invited patients to a face-to-face consult-
ation. Prior to the consultation, pharmacists completed
a paper-based medication review of each patient’s
medical record and patients were asked to complete a
pain diary to inform the consultation. A pharmaceutical
care plan was agreed between the pharmacist and the
patient. The plan assessed and documented relevant
medical history and current conditions; known allergies
and adverse drug reactions; relevant laboratory results;
pain-related medications prescribed in the previous
10 years; current pain-related prescription medications;
current symptoms; lifestyle issues, including units of
alcohol consumed per week; recommendations for
changes to medication (if any); whether non-
pharmaceutical treatments had been considered; and
any other relevant issues. Copies of the pain diary and
pharmaceutical care plan are available from the authors
on request. At the end of the consultation any required
prescriptions for medicines were issued by the pharma-
cist. Owing to Controlled Drug (CD) regulations in
place at the time, prescribing for CDs was performed
using a supplementary prescribing CMP,17 rather than
independent prescribing. Patients were followed up
either by phone or face-to-face, at each pharmacist’s
discretion.
‘Review arm’: The pharmacists conducted a paper-
based medication review focussed on pain-related pre-
scription medications, before creating a pharmaceutical
care plan which detailed any recommendations for
medication changes. The plan was passed to the
patient’s GP for implementation. The GPs were asked
subsequently about actions taken as a result of the
recommendations.
Treatment as usual: Patients received standard general
practice care.
Outcome measures
A core aim of this exploratory RCT was to ﬁnalise the
selection of outcome measures for a subsequent multi-
centred RCT. In the Current Controlled Trials
Registration (ISRCTNO6131530) we speciﬁed both
primary and secondary outcome measures (primary:
SF12, Health Utilities Index (HUI); secondary: chronic
pain grade (CPG), HADS) based on our judgement fol-
lowing the earlier feasibility study.15 However in practice,
all outcomes were considered equal and no single
measure was deﬁned as the primary outcome, for
example, for the purpose of a sample size calculation
(see below). These four outcome measures are
described below. Inclusion of both pain-speciﬁc and
generic outcome measures was based on Initiative on
Methods, Measurement and Pain Assessment in Clinical
Trials (IMMPACT) recommendations18 and an earlier
feasibility study.15
The SF-12v2 is a generic health and functioning
scale,19 previously used in population-based studies of
pain.20 21 A Physical (PCS) and Mental Component
Score (MCS) were calculated, ranging from 0 to 100; a
higher score indicates better functioning.
The HUI3 is a preference-based system for measuring
comprehensive health status and health-related quality
of life (HRQL).22 It provides descriptive evidence and a
score for each dimension of health (vision, hearing,
speech, ambulation/mobility, pain, dexterity, self-care,
emotion and cognition) and an HRQL score for overall
health. Each dimension has 3–6 levels. Owing to the cost
of the additional license fee to score data from this
measure, this instrument was not subsequently analysed.
The CPG23 is a seven-item scale which assesses pain
severity on two dimensions: disability and intensity. The
scale classiﬁes pain according to the level of intensity
and disability (I (low disability–low intensity) to IV (high
disability–severely limiting)).
The Hospital Anxiety and Depression Scale (HADS)24
is a 14-item screening instrument which identiﬁes the
possible and probable caseness of anxiety (7 items
(HADS-A)) and depression (7 items (HADS-D)); each
item scored from 0 (not present) to 3 (highly present).
Standard thresholds and previously used labels25 were
applied: no depression/anxiety (0–7), mild (8–10),
moderate (11–15) or severe (>15)).
Data collection
Participant questionnaires
Questionnaires were posted to participants at baseline
(pre-randomisation) and 3 and 6 months post-
randomisation (follow-up was conducted between July
2010 and January 2011). Up to two reminders were sent.
Questionnaire content included the outcome measures
described earlier together with items on: demographic
status (baseline only); screening items to conﬁrm eligi-
bility (baseline only); duration of pain condition (base-
line only); location of pain; Morisky Medication
Adherence Scale 4 (MMAS-4);26 participant satisfaction
(11 statements derived from the feasibility study for the
prescribing arm (3 months only)) and additional com-
ments by participants. The MMAS-4 provides a score of
self-reported adherence to medication regimen. Scores
range from 0 (low adherence) to 4 (high adherence).
Follow-up interviews with staff
Post-intervention, all pharmacists and all GPs in partici-
pating practices were invited to take part in semistruc-
tured interviews, carried out face-to-face when possible,
otherwise by telephone. Interviews were taped, tran-
scribed verbatim and content analysis was carried out.
Sample size
As this was an exploratory trial to estimate the effect size
for a larger trial, no formal sample size calculation was
possible.27 We aimed to recruit 30 participants per prac-
tice (n=180; with an additional six per practice for train-
ing purposes, that is, 216 in total). This was deemed
sufﬁcient to give reliable effect size estimates for the
outcome measures of health status or CPG.
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Figure 1 CONSORT flow diagram.
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Data management and analysis
Data were entered into identical SPSS databases at each
site and accuracy checks carried out on 10% before
databases were merged. Descriptive statistics included
means and SD for normally distributed continuous data,
medians (IQR) for skewed continuous data and percen-
tages (n) for categorical data. Analysis was conducted on
an intention-to-treat basis for participants with complete
data on relevant measures using SPSS V.18.
Exploratory analyses for parametric data included the
paired t-test for within-arm comparisons of mean differ-
ence between baseline and 6 months and one-way ana-
lysis of varience for between arm comparisons of mean
difference. For non-parametric data it included the
Wilcoxon signed rank test for within-arm comparisons of
median difference and the Kruskal-Wallis test for
between arm comparisons of median difference.
Categorical data were analysed using the marginal
Table 1 Baseline demographic, socioeconomic and pain data of patients by study arm, prescribing, review and treatment as
usual (TAU)
Prescribing* (n=68) Review* (n=62) TAU* (n=63)
Age: mean (SD) 66.1 (12.1) 65.7 (14.2) 64.9 (11.6)
Missing 1 1 0
Gender (% female) 54.4 (37) 74.2 (46) 58.7 (37)
Marital status
Married 43 30 41
Single 6 6 3
Divorced/widow 10 21 13
Other 6 4 6
Missing 3 1 0
Highest educational level achieved
No qualifications 30 27 21
O grade or equivalent 12 6 14
Higher/A-level/NVQ3/SVQ3 6 8 7
Tertiary education/NVQ4/NVQ5 18 17 14
Other 2 1 4
Missing 0 3 3
Employment status
Employed 16 14 9
Unemployed 3 5 1
Retired 38 35 34
Long-term sick/disabled 7 5 9
Other 3 2 7
Missing 1 1 3
Household annual income before tax
Less than £9999 13 15 10
£10000–£14999 14 18 22
£15000–£24999 14 12 12
£25000–or more 22 11 8
Missing 5 6 11
Ethnic group
Caucasian 67 62 61
Other 1
Missing 0 0 2
Pain duration (years)
<1 3 2 4
1–3 12 12 7
3–5 10 13 9
5–10 17 13 15
>10 26 22 28
Pain localisation (%, n)
Back 27.9 (19) 32.3 (20) 20.6 (13)
Neck, shoulders 7.4 (5) 9.7 (6) 9.5 (6)
Limbs or hips 42.6 (29) 30.6 (19) 50.8 (32)
Other 8.8 (6) 4.8 (3) 7.9 (5)
Missing 9 14 7
*Denominator based on numbers allocated to the specific arms, minus any exclusions due to protocol violations.
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homogeneity test for within-arm comparisons (with null
hypotheis that the distribution of CPG grade or HADS
group does not change between baseline and 6 month
follow-up) and the χ² test for between-arm comparisons;
analyses reported here are based on 6 month follow-up
data (other than for participant experiences). Within-
arm effect sizes, expressed in terms of a Pearson correl-
ation coefﬁcient (r) have been calculated using the for-
mulas from Rosenthal.28 Effect sizes can be directly
compared using Cohen’s29 criteria of r=0.1 (small
effect); r=0.3 (medium effect) and r=0.5 (large effect).
RESULTS
Response rates and demography
Six of the seven practices approached participated. GPs
excluded 12% (392/3281) of patients, mostly those with
dementia. There was no statistically signiﬁcant difference
between participants and non-participants in terms of
age, gender and index of multiple deprivation. Figure 1
shows the ﬂow of participants through the study. Overall,
the consent rate was 25% (356/1397) and the recruit-
ment rate was 14% (196/1397).
Eighty-six per cent of participants (251/289) returned
baseline questionnaires, of whom 232 were randomised
(36 participants were randomised to one of the two
intervention arms for training purposes and were not
included in any further analysis and 19 were not
included as the recruitment target had been met). The
overall follow-up rate at 3 months was 86% (161/187)
and at 6 months 84% (152/180).
As shown in table 1, groups were similar at baseline
for demographic and socioeconomic variables and pain
data. Most participants were married, Caucasian and
female, older (mean (SD) age 65 (12.6) years), had an
annual income of <£25 000 and had suffered from pain
for at least 5 years. Most (57%; 103/181) reported being
fully adherent to their medication regimen (MMAS-4,
median 4.0 (IQR 3.0–4.0); 15 missing MMAS scores).
In the prescribing arm, 78% (53/68) attended an
initial prescribing consultation, 31 had at least one
planned follow-up (of which 34/37 were conducted by
phone) and 130 recommendations were made for 92%
(49/53) of participants seen. Examples are shown in
box 1. The median time taken for the note-based record
review was 35 min (IQR 20.0, 45.0), the consultation was
30 min (IQR 20.0, 40.0), careplan preparation 10 min
(IQR 10.0, 20.0) and median duration of follow-ups was
10 min (IQR 5.0–15.0).
In the review arm 97% (60/62) of participants’
records were reviewed (note there was one postrandomi-
sation exclusion) for whom 197 recommendations were
made. Where GP feedback was provided (n=48), they
generally agreed with pharmacists’ recommendations,
which were fully implemented for 20 participants (2 by
the pharmacist following request by GP), partially for 19
participants and not at all for nine participants. The
median time taken for the note-based record review was
30 min (IQR 24.3, 45.0), and careplan preparation was
10 min (IQR 5.0, 20.0).
Clinical outcome measures
Table 2 shows the mean (SD) or median (IQR) of the
CPG for each arm at baseline and 6-month follow-up.
Table 3 shows the SF-12 scores and table 4 shows the
HADS-A and HADS-D results.
In the prescribing arm, there was a statistically signiﬁ-
cant within arm improvement for the CPG intensity
(p=0.002, effect size (r)=0.45) and disability (p=0.003,
effect size (r)=0.43) subscales and between arms on the
intensity subscale (p=0.02), but not the disability subscale
(p=0.55; table 2). There was a signiﬁcant within-arm
improvement in overall CPG grade in the prescribing
(p=0.003) and review arm (p=0.001), but not in the TAU
arm. The SF-12 PCS showed a statistically signiﬁcant
within arm improvement in the TAU arm (p=0.02, effect
size (r)=0.35; table 3), but not between trial arms. The
SF-12 MCS showed a statistically signiﬁcant deterioration
in the TAU arm (p=0.002, effect size (r)=0.45; (table 3),
as did the HADS-D (p=0.03, table 4). Analysis was also
carried out on the non-categorised HADS scores which
showed a statistically signiﬁcant improvement within the
prescribing arm for Depression (p=0.022) and Anxiety
(p=0.007). These were both signiﬁcant between groups
(p=0.022 and p=0.045, respectively; table 5).
Acceptability of the pharmacist prescribing intervention
All six pharmacists and 56% of the GPs (23/41) were inter-
viewed. All pharmacists and most GPs were positive about
the intervention, although some GPs suggested that the
pharmacists’ recommendations had been minor and ques-
tioned the cost-effectiveness of the service. Patient partici-
pants were generally positive about the pharmacist
prescribing service although some concerns were identi-
ﬁed, as illustrated by the quotes shown in box 2.
DISCUSSION
Principal findings
This exploratory RCT of pharmacist-led management of
patients with chronic pain suggests that pharmacist
Box 1 Examples of pharmacist interventions in the pre-
scribing arm
Changes to pain management: ‘use paracetamol regularly’, ‘take
tramadol if needed’ ‘add piroxicam gel PRN’, ‘given web links to
self help groups’
Compliance aid: ‘gave written times that this drug could be taken’
Addressing side effects/safety: ‘take paracetamol after initial
NSAID’, ‘take senna’, ‘ordered blood monitoring’, ‘stop use of two
NSAIDS’
General health: ‘discussed weight loss’, ‘invited to practice nurse
for BP’, ‘glucose, lipids and lifestyle update’
Cost minimisation: ‘change aspirin EC to plain’.
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Table 2 Mean (SD) CPG intensity, median (IQR) CPG disability and count CPG grade at baseline, 6-month follow-up and difference between the two assessment points
for each arm, prescribing, review and treatment as usual (TAU)
Prescribing Review TAU
p Value
(between groups†)
N* Mean (SD) N* Mean (SD) N* Mean (SD)
Baseline CPG intensity 47 66.1 (16.0) 45 68.4 (17.6) 54 65.4 (18.0)
6-month follow-up CPG intensity 58.1 (19.5) 67.4 (21.7) 65.6 (19.6)
Difference CPG intensity −8.0 (16.3) −1.0 (16.0) 0.2 (14.9)
p (within groups‡) 0.002 0.67 0.93 0.02
Effect size (r) 0.45 0.07 0.01
Median (IQR) Median (IQR) Median (IQR)
Baseline CPG disability 48 60.0 (30.0;75.8) 46 66.7 (45.0;80.0) 53 56.7 (36.7;80.0)
6-month follow-up CPG disability 40.0 (20.0;60.0) 53.3 (29.2;73.3) 50.0 (25.0;80.0)
Difference CPG disability −8.3 (−23.3;0.0) −3.3 (−16.7;10.0) −3.3 (−21.7;5.0)
p (within groups‡) 0.003 0.15 0.05 0.55
Effect size (r) 0.43 0.20 0.26
Baseline CPG grade 44 Count (%) 44 Count (%) 48 Count (%)
I 5 (11.4) 3 (6.8) 5 (10.4)
II 16 (36.4) 9 (20.5) 13 (27.1)
III 7 (15.9) 10 (22.7) 13 (27.1)
VI 16 (36.4) 22 (50.0) 17 (35.4)
6-month follow-up CPG grade
I 13 (29.5) 8 (18.2) 6 (12.5)
II 13 (29.5) 15 (34.1) 17 (35.4)
III 8 (18.2) 8 (18.2) 11 (22.9)
IV 10 (22.7) 13 (29.5) 14 (29.2)
Difference CPG grade
≤−1 21 (47.7) 17 (38.6) 15 (31.2)
0 17 (38.6) 25 (56.8) 25 (52.1)
≥1 6 (13.6) 2 (4.5) 8 (2.1) 0.16
p (within groups†) 0.003 0.001 0.17
p Values for within-arm and between-arm differences are also reported.
*Number of participants in each group who completed the appropriate part of the CPG at both baseline and follow-up.
†From analysis of variance on mean difference, Kruskall-Wallis on median difference or χ2 test on difference in CPG grade as appropriate.
‡From paired t test, Wilcoxon signed rank test or marginal homogeneity test as appropriate.
CPG, Chronic Pain Grade.
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prescribing (and possibly pharmacist review alone) may
be effective in improving pain-related outcomes and be
acceptable to both patients and most professionals.
There was an indication of a positive effect on emotional
health, but no measurable effect on general health.
Strengths and weaknesses
This was the ﬁrst RCT to assess clinical and humanistic
outcomes after pharmacist prescribing for any clinical
condition compared with usual GP care, and the ﬁrst
RCT to speciﬁcally assess pharmacist-led management of
chronic pain, compared with usual GP care. It was based
on extensive development and feasibility work14 15 in
line with MRC framework for development and evalu-
ation of complex interventions.30 A range of validated
outcome measures was included, as well as a parallel
qualitative process evaluation which assessed satisfaction
and acceptability. The inclusion of six practices and
their associated pharmacists from both Scotland and
England increased the generalisability of the ﬁndings.
Pharmacists received formal training and agreed and
used a common treatment algorithm which should have
increased standardisation of treatment. The preponder-
ance of women (overall 62%) and average age of
65 years reﬂects the wider chronic pain population1 as
does the distribution of pain site.31 32
There were, however limitations. Although high
follow-up response rates were achieved at both 3 (86%)
and 6 months (85%) only 25% of eligible patients
entered the trial. This low initial consent rate is in line
with other studies,33 34 but may cause unknown biases
including problems of generalisability, as does the solely
Caucasian ethnicity. Concerns identiﬁed by participants
during the formal feedback, for example, having too
many people involved in one’s care may have contribu-
ted to poor response rates and rewording of participant
recruitment documentation to reassure participants of
the role of the pharmacist could address this. More par-
ticipants withdrew in the prescribing arm compared with
the other two arms, which might be attributed to the
need for an additional practice visit. The study was an
exploratory trial so no formal power calculation was
undertaken. However, because there were no published
MIDs available to estimate effect size for the outcomes
in this population, it was important to present the actual
clinical magnitude of change in outcome at 6 months
alongside a statistical assessment of this change (p
value). This allows an assessment of both clinical and
statistical signiﬁcance simultaneously with the caveat that
this is an exploratory study. With around 50 patients per
arm, this was deemed sufﬁcient numbers to examine the
change in outcome measures with appropriate
within-group and between-group univariate statistical
tests. Owing to the nature of the intervention, no partici-
pants were blind to their group allocation, and so some
outcomes, especially the qualitative components, may
have been affected by social desirability bias.
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Table 4 The Hospital Anxiety and Depression Scale-Depression (HADS-D) and HADS-Anxiety (HADS-A) count of patients
according to severity (normal, mild, moderate or severe) and the difference in severity category between the two assessment
points for each arm, prescribing, review and treatment as usual (TAU)*
N* Prescribing N* Review N* TAU
p Value
(between groups†
Baseline HADS-D 44 Count (%) 45 Count (%) 53 Count (%)
Normal 32 (72.7) 31 (68.9) 38 (71.7)
Mild 8 (18.2) 11 (24.4) 7 (13.2)
Moderate 3 (6.8) 3 (6.7) 8 (15.1)
Severe 1 (2.3) 0 0
6-month follow-up HADS-D
Normal 32 (72.7) 32 (71.1) 32 (60.4)
Mild 7 (15.9) 6 (13.3) 10 (18.9)
Moderate 5 (11.4) 6 (13.3) 8 (15.1)
Severe 0 1 (2.2) 3 (5.7)
Difference HADS-D
≤–1 5 (11.4) 4 (8.9) 2 (3.8)
0 34 (77.3) 37 (82.0) 40 (75.5)
≥1 5 (11.4) 4 (8.9) 11 (20.8) 0.32
p (within groups‡) 1.0 0.71 0.03
Baseline HADS-A 44 Count (%) 43 Count (%) 48 Count (%)
Normal 25 (56.8) 30 (69.8) 29 (60.4)
Mild 8 (18.2) 7 (16.3) 9 (18.8)
Moderate 8 (18.2) 5 (11.6) 8 (16.7)
Severe 3 (6.8) 1 (2.3) 2 (4.2)
6-month follow-up HADS-A
Normal 27 (61.4) 29 (67.4) 32 (66.7)
Mild 7 (15.9) 6 (14.0) 5 (10.4)
Moderate 8 (18.2) 6 (14.0) 10 (20.8)
Severe 2 (4.5) 2 (4.7) 1 (2.1)
Difference HADS-A
≤–1 6 (13.6) 3 (7.0) 10 (20.8)
0 35 (79.5) 33 (76.7) 29 (60.4)
≥1 3 (6.8) 7 (16.3) 9 (18.8) 0.14
p (within groups‡) 0.25 0.21 0.55
Within-arm and between-arm p values are also reported.
*Number of participants in each group who completed the appropriate part of the HADS at both baseline and follow-up.
†From χ² test on difference in HADS.
‡From marginal homogeneity test.
Table 5 Median Hospital Anxiety and Depression Scale-Depression (HADS-D) and HADS-Anxiety (HADS-A) scores (IQR)
at baseline and 6-month follow-up and difference between the two assessment points for each arm, prescribing, review and
treatment as usual (TAU)
Prescribing Review TAU
N* Median (IQR) N* Median (IQR) N* Median (IQR) p Value
(between groups)
Baseline HADS-D 42 5.0 (3.0;8.0) 44 4.5 (2.3;8.0) 51 5.0 (3.0;8.0)
6-month follow-up HADS-D 4.0 (2.0;8.0) 5.0 (2.0;8.8) 5.0 (2.0;10.0)
Difference HADS-D −1.0 (−2.0;0.0) 0.0 (−1.0;1.8) 0.0 (−1.0;2.0) 0.02
p (within groups) 0.02 0.33 0.22
Baseline HADS-A 44 7.0 (3.3;10.8) 43 5.0 (3.0;10.0) 48 6.0 (4.0;10.0)
6-month follow-up HADS-A 5.0 (2.3;9.8) 6.0 (3.0;9.0) 7.0 (4.0;10.0)
Difference HADS-A −1.0 (−2.0;0.0) 0.0 (−2.0;2.0) 0.5 (−3.0;2.0) 0.05
p (within groups) 0.01 0.45 0.81
Within-arm and between-arm p values are also reported.
*Number of participants in each group who completed the appropriate part of the HADS at both baseline and follow-up.
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Our outcome measures were self-reported, but this is
the norm in pain studies as pain is a subjective experi-
ence.18 Furthermore we do not know how important the
observed differences were to participants. Following pre-
cedents set in previous research,25 and because there is
no consensus on an alternative measure35 we used the
HADS as a tool to classify people by severity of depres-
sion and anxiety. However it is strictly a screening tool,
and the four levels of severity have not been formally
validated. We therefore also compared outcomes using it
as a continuous scale.
Relationship with other studies
This study is important because no other RCT has evalu-
ated pharmacist prescribing and few studies, and import-
antly no RCTs, have evaluated pharmacist interventions
for pain. In pharmacist prescribing most research has
focused on reported experiences of professionals and
patients, and not used validated outcome measures. Yet
pharmacist prescribing is now widely practised. For pain,
there have been a few small studies. Briggs et al36 con-
ducted a small before-and-after evaluation (involving 65
patients) of a nurse and pharmacist-led chronic pain
clinic in primary care. Pain intensity visual analogue
scale scores reduced signiﬁcantly over 6 months.
Another evaluation of 26 patients using a medication
review service provided jointly by a physiotherapist and
pharmacist in the UK, reported improvement in pain
control for 88% of patients.37
The CPG was found to show a graded effect across the
three arms, showing discrimination with both direction
and strength of improvement, suggesting maximum
beneﬁt for those in the pharmacist prescribing arm.
However, the reduction in overall score appears to be
mediated by a change in the intensity of pain subscale
rather than in pain-related disability. The effect size of
0.45 suggests this could be an important difference. In
contrast, the SF-12, a measure of general health and
functionality showed no signiﬁcant difference between
intervention arms, reﬂecting either no effect or or lack
of power to detect an effect.
While most participants in this study were already
within the normal range on the HADS scale, and there-
fore had minimal chance of improvement, there were
nonetheless suggestions of better ourcomes in partici-
pants in the prescribing arm. Including a range of
instruments is in line with IMMPACT recommenda-
tions,38 which state that focus should be on the whole
person, not just about pain. However, this needs to be
balanced with minimising participant burden.
Explanations, implications and future research
The number of pharmacist’s recommendations per par-
ticipant was higher in the review arm than in the pre-
scribing arm. This might seem contradictory to the
possible greater beneﬁt found in the prescribing arm.
However, in the prescribing arm pharmacists met the
participant and may have more readily identiﬁed and
dismissed suggestions previously tried. The interview
feedback highlighted that some recommendations for
change, while sensible, had been tried already. This
might also be the reason why there were only 60% of
pharmacist recommendations with which the GP fully
agreed. Self-reported adherence to medication at base-
line was good. Despite this, the pharmacists still
improved pain outcomes in the prescribing arm. This
could have been due to changes in medications and/or
participant education about optimal timing for adminis-
tration of analgesic medicines. Further research is
needed to conﬁrm the beneﬁcial effect of pharmacist
prescribing and its sustainability.
CONCLUSION
Our results suggest that pharmacist prescribing (and
possibly pharmacist review alone) for patients with
chronic pain is feasible, acceptable and may lead to
improvements in pain and other measures. A larger fully
powered trial is now needed to conﬁrm these ﬁndings.
Box 2 Examples of quotes from pharmacists (n=6),
general practitioners (GPs) (n=23) and patient participants
(n=40) on the prescribing intervention
Pharmacists (from interviews):
Satisfying (n=6):‘contact with patients’, ‘being able to help
patients’, ‘being able to make a difference to long-standing pai-
n’...’even in small ways’
Interesting (n=6):‘learning about pain’
Challenging (n=6):‘complex, chronically ill patients’
GPs (from interviews):
Support for the service (n=17): it’s been a very positive thing’
Agreement with pharmacists’ recommendations (n=23): ‘oh
very reasonable suggestions’, ‘tinkering round the edges’, ‘had
been tried already’.
Trust in the practice pharmacist (n=23):‘I respect his profes-
sional judgement’
Cost effectiveness (n=6): ‘if there’s limited resources do we
want to spend the money on a pharmacist’.
Patients (from 3-month questionnaire):
Closed questions:
Proportion agreeing that:
The pharmacist was interested in them (89%; 39/44)
They were totally satisfied (85%; 39/46)
They were told about their treatment (82%; 38/46)
Their consultation was thorough (79%; 34/44)
They would have liked more time (9%;4/44)
They would have preferred to see their GP (9%; 4/44)
Too many people were now involved in their treatment
(11%; 5/44).
Open text questions:
Positive (n=39): ‘She was professional, relaxed, pleasant and
interested. Excellent!’
Negative (n=1): ‘A waste of time, altered my tablets which
made my pain worse’.
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